VE
Vera Therapeutics, Inc.
VERA · NASDAQ
$35.05 +3.36% (+$1.14)
1M +10.81%
Market Cap $2.41B
P/E Ratio -
Div. Yield -
ROE 84.13%
Bulios Fair Price
$32.62
6.9% downside
Current Price
$35.05
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VERA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
26 /100
Expensive P/B 5.92x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 98.83%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 85.78%
ROE 84.13%
ROA 75.40%
Debt
69 /100
Low Debt/Equity 0.18x
Current ratio 10.92x
Int. coverage -34.70x
Stability
50 /100
Moderate Beta 0.95x
EPS volatility 51.20%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VERA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Marshall Fordyce
Employees
361
Headquarters
Brisbane
Upcoming events
04 NOV
Earnings
Upcoming earnings report